-
【和文】
-
1. 【腫瘍循環器学-新しい学際領域の最新知見-】CTR-CVTの病態と機序 がん免疫療法 CAR-T細胞療法に伴う心血管有害事象の病態と機序. 日本臨床 2024;82:138-43.
吉原 哲, 砂山 勇, 吉原 享子, 閔 庚徳.
-
2. 多発性骨髄腫に対するCAR-T細胞療法の役割とそのための施設連携. 臨床血液 2024;65:1042-8.
吉原 哲.
-
3. 【多発性骨髄腫と類縁疾患】多発性骨髄腫に対する最新治療戦略と展望. 日本内科学会雑誌 2023;112:1202-9.
吉原 哲, 吉原 享子.
-
4. 【新リンパ腫学-基礎・臨床の最新動向-】悪性リンパ腫に対する新規治療戦略の現状と展望 悪性リンパ腫に対するキメラ抗原受容体T細胞療法の現在地と展望. 日本臨床 2023;81:491-7.
吉原 哲.
-
5. 【多発性骨髄腫update-診断・治療の最新動向-】診断と治療 治療の進歩 ハイリスク骨髄腫に対する治療戦略. 日本臨床 2023;81:899-907.
吉原 哲.
-
6. 【血液疾患における抗体医薬と免疫細胞療法の新たな展開】急性骨髄性白血病に対する抗体医薬と免疫療法の開発動向. 血液内科 2022;85:54-9.
吉原 哲.
-
【英文】
-
1. Pretransplantation predictors of survival in nonremission acute myeloid leukemia treated with haploidentical transplantation using steroid-based GVHD prophylaxis. Ann Hematol 2024;103:1363-72.
Teramoto M, Tamaki H, Kaida K, Samori M, Takahashi-Hirata S, Utsunomiya N, Katayama A, Fukunaga K, Inoue T, Yoshihara K, Ikegame K, Okada M, Yoshihara S.
-
2. Individualized rabbit anti-thymocyte globulin dosing in adult haploidentical hematopoietic cell transplantation with high-risk hematologic malignancy: Exposure-response analysis and population pharmacokinetics simulations. Am J Hematol 2024;99:387-95.
Teramoto M, Takahashi T, Matsumoto K, Jaber M, Kaida K, Tamaki H, Ikegame K, Yoshihara S.
-
3. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol 2023;202:256-66.
Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y.
-
4. Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy. Leuk Res Rep 2022;18:100338.
Yoshihara K, Orihara Y, Hoshiyama T, Tamaki H, Sunayama I, Matsuda I, Nishikawa A, Kumamoto T, Samori M, Utsunomiya N, Min KD, Asakura M, Hirota S, Ishihara M, Higasa S, Yoshihara S.
-
5. T-cell lymphoma, B-cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone. EJHaem 2022;3:211-4.
Yoshihara K, Nannya Y, Matsuda I, Samori M, Utsunomiya N, Okada M, Hirota S, Ogawa S, Yoshihara S.
-
6. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 2022;28:365.e1-.e7.
Jo T, Yoshihara S, Hada A, Arai Y, Kitawaki T, Ikemoto J, Onomoto H, Sugiyama H, Yoshihara K, Obi N, Matsui K, Niwa N, Nakagawa Y, Kanda J, Kondo T, Saida S, Kato I, Hiramatsu H, Adachi S, Takita J, Takaori-Kondo A, Nagao M.
-
7. Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma. Hematology 2021;26:388-92.
Yoshihara S, Yoshihara K, Shimizu Y, Imado T, Takatsuka H, Kawamoto H, Misawa M, Ifuku H, Ohe Y, Okada M, Fujimori Y.
-
8. Impact of the use of hydroxyethyl starch in granulocyte apheresis using Spectra Optia. Transfus Med 2021;31:365-70.
Yoshihara S, Ikemoto J, Onomoto H, Sugiyama H, Okuda N, Fukunaga K, Yoshihara K, Kaida K, Ikegame K, Tamaki H, Okada M, Osugi Y, Yamahara K, Higasa S, Fujimori Y.
-
9. High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy. Hemasphere 2021;5:e628.
Yoshihara K, Matsuda I, Utsunomiya N, Samori M, Hirata S, Okada M, Hirota S, Higasa S, Yoshihara S.
-
10. Posttransplant Hemophagocytic Lymphohistiocytosis Driven by Myeloid Cytokines and Vicious Cycles of T-Cell and Macrophage Activation in Humanized Mice. Front Immunol 2019;10:186.
Yoshihara S, Li Y, Xia J, Danzl N, Sykes M, Yang YG.
-
11. Update on granulocyte transfusions: accumulation of promising data, but still lack of decisive evidence. Curr Opin Hematol 2016;23:55-60.
Yoshihara S, Ikemoto J, Fujimori Y.
-
12. The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant 2012;47:1499-506.
Yoshihara S, Taniguchi K, Ogawa H, Saji H.
-
13. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012;47:508-15.
Yoshihara S, Maruya E, Taniguchi K, Kaida K, Kato R, Inoue T, Fujioka T, Tamaki H, Ikegame K, Okada M, Soma T, Hayashi K, Fujii N, Onuma T, Kusunoki Y, Saji H, Ogawa H.
-
14. Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. Bone Marrow Transplant 2012;47:369-73.
Yoshihara S, Ikegame K, Taniguchi K, Kaida K, Kim EH, Nakata J, Kato R, Inoue T, Fujioka T, Tamaki H, Okada M, Soma T, Ogawa H.
-
15. Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome. Bone Marrow Transplant 2012;47:669-76.
Yoshihara S, Ikegame K, Kaida K, Taniguchi K, Kato R, Inoue T, Fujioka T, Tamaki H, Okada M, Soma T, Ogawa H.
-
16. Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: an easily overlooked but significant pattern of relapse. Biol Blood Marrow Transplant 2012;18:1800-7.
Yoshihara S, Ando T, Ogawa H.
-
17. Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors. Bone Marrow Transplant 2012;47:1338-42.
Taniguchi K, Yoshihara S, Maruya E, Ikegame K, Kaida K, Hayashi K, Kato R, Inoue T, Fujioka T, Tamaki H, Okada M, Onuma T, Fujii N, Kusunoki Y, Soma T, Saji H, Ogawa H.
-
18. Intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning treatment: a phase I study. Biol Blood Marrow Transplant 2012;18:633-9.
Okada M, Yoshihara S, Taniguchi K, Kaida K, Ikegame K, Kato R, Tamaki H, Inoue T, Soma T, Kai S, Kato S, Ogawa H.
-
19. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:749-59.
Yoshihara S, Yanik G, Cooke KR, Mineishi S.
-
20. Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplant 2005;35:1195-200.
Yoshihara S, Tateishi U, Ando T, Kunitoh H, Suyama H, Onishi Y, Tanosaki R, Mineishi S.
